Dominick Colangelo
Vorstandsvorsitzender bei VERICEL CORPORATION
Vermögen: 10 Mio $ am 30.04.2024
Aktive Positionen von Dominick Colangelo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VERICEL CORPORATION | Direktor/Vorstandsmitglied | 01.03.2013 | - |
Vorstandsvorsitzender | 01.03.2013 | - | |
Präsident | 01.03.2013 | - | |
TREVI THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 29.06.2020 | - |
Independent Dir/Board Member | 29.06.2020 | - |
Karriereverlauf von Dominick Colangelo
Ehemalige bekannte Positionen von Dominick Colangelo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | 23.02.2011 | 15.05.2012 |
Vorstandsvorsitzender | 01.12.2008 | 15.05.2012 | |
Präsident | 01.12.2008 | 15.05.2012 | |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Geschäftsführer | 01.01.2005 | 11.12.2008 |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Chief Investment Officer | - | 07.12.2005 |
Private Equity Investor | - | 07.12.2005 | |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.01.1995 | - |
Ausbildung von Dominick Colangelo
State University of New York at Buffalo | Undergraduate Degree |
Duke University School of Law | Graduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
2 |
Operativ
Director/Board Member | 3 |
Chief Executive Officer | 2 |
President | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
VERICEL CORPORATION | Health Technology |
Private Unternehmen | 4 |
---|---|
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
Trevi Therapeutics, Inc. |
- Börse
- Insiders
- Dominick Colangelo
- Erfahrung